Castle Biosciences, Inc. (CSTL)

Market Cap	700.99M
Revenue (ttm)	346.27M
Net Income (ttm)	-9.47M
Shares Out	29.01M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,624
Open	24.05
Previous Close	23.96
Day's Range	23.31 - 24.27
52-Week Range	14.59 - 35.84
Beta	1.13
Analysts	Strong Buy
Price Target	37.67 (+55.89%)
Earnings Date	Nov 3, 2025

About CSTL

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose me...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 25, 2019
• Employees: 761
• Stock Exchange: NASDAQ
• Ticker Symbol: CSTL
• Website: https://castlebiosciences.com

Analyst Summary

According to 6 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $37.67, which is an increase of 55.89% from the latest price.

Price Target

$37.67

(55.89% upside)

Analyst Consensus: Strong Buy